黄芪多糖联合碘-125治疗中晚期非小细胞肺癌的临床研究

孙芳; 宋波; 王燕虎; 贾小军

doi:10.11653/syfj2014010189

您当前的位置：

首页 >

文章列表页 >

黄芪多糖联合碘-125治疗中晚期非小细胞肺癌的临床研究

更新时间：2024-01-04

- 黄芪多糖联合碘-125治疗中晚期非小细胞肺癌的临床研究
- Clinical Study of Astragal Polysaccharides Combined With Iodine-125 in Treatment of Advanced Non-small Cell Lung Cancer
- 中国实验方剂学杂志 2014年20卷第1期页码：189-192
- 作者机构：
- 作者简介：
- 基金信息：
  
  云南省“十二五”特色优势“中西医结合”学科资助项目（30160800101）
- DOI：10.11653/syfj2014010189
  中图分类号：
- 纸质出版日期：2014
- 稿件说明：
移动端阅览
孙芳, 宋波, 王燕虎, 等. 黄芪多糖联合碘-125治疗中晚期非小细胞肺癌的临床研究[J]. 中国实验方剂学杂志, 2014,20(1):189-192.

SUN Fang, SONG Bo, WANG Yan-hu, et al. Clinical Study of Astragal Polysaccharides Combined With Iodine-125 in Treatment of Advanced Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(1): 189-192.
孙芳, 宋波, 王燕虎, 等. 黄芪多糖联合碘-125治疗中晚期非小细胞肺癌的临床研究[J]. 中国实验方剂学杂志, 2014,20(1):189-192. DOI： 10.11653/syfj2014010189.

SUN Fang, SONG Bo, WANG Yan-hu, et al. Clinical Study of Astragal Polysaccharides Combined With Iodine-125 in Treatment of Advanced Non-small Cell Lung Cancer[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(1): 189-192. DOI： 10.11653/syfj2014010189.

摘要

目的：探讨黄芪多糖（APS）联合碘-125（I125）治疗中晚期非小细胞肺癌（NSCLC）的临床疗效及作用机制。方法：将60例中晚期NSCLC患者随机按住院前后顺序分为观察组和对照组各30例，对照组采用I125粒子植入方法，观察组在对照组治疗的基础上加用APS 250 mg，静脉滴注，1次/d。疗程42 d。观察治疗前患者瘤体大小，进行治疗前后KPS评分，检测治疗前后细胞免疫功能（NK，CD3+，CD4+，CD8+）和血清癌胚抗原（CEA）和细胞角蛋白19片段（CYFRA-21-1）水平。结果：治疗后观察组和对照组总有效率分别为83.33%和73.33%，两组比较差异无显著性意义；治疗后观察组卡氏评分提高+稳定率为90.0%，优于对照组的63.3% （P<0.01）；治疗后对照组NK，CD3+，CD4+，CD8+及CD4+/CD8+变化不明显，治疗后观察组NK，CD3+，CD4+及CD4+/CD8+上升并高于对照组，CD8+下降并低于对照组（P<0.01）；两组血清CEA，CYFRA-21-1水平均较治疗前下降，治疗后观察组低于对照组（P<0.01）。结论：APS联合I125治疗中晚期NSCLC，能提高患者生活质量，提高患者免疫功能，并具有一定的抗肿瘤作用，对I125起到增效作用，值得进一步研究。

Abstract

Objective: To investigate the effect of Astragal Polysaccharides combined with Iodine-125(I125)in the treatment of advanced non small cell lung cancer (NSCLC) clinical curative effect and mechanism of action. Method: A total of 60 cases of patients of advanced NSCLC were randomly by digital divided into observation group and control group with 30 cases in each group

the control group using I125 particle implantation method

the observation group was treated with Astragal Polysaccharide (APS) 250 mg

once a day. The course of treatment was 42 days. Before treatment in patients with tumor size

KPS score before and after treatment

the cell immune function were detected before and after treatment (NK

CD3+

CD4+

CD8+) and serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA-21-1) level. Result: after treatment

the observation group and the control group the total effective rate were 83.33% and 73.33%

no significant difference between the two groups;after treatment

the observation group KPS increase and stable rate were 90.0%

more than 63.3% of control group (P<0.01);the control group after treatment NK

CD3+

CD4+

CD8+ and CD4+/CD8+ did not change significantly

after treatment were observed in group NK

CD3+

CD4+ and CD4+/CD8+ increased and higher than that of the control group

CD8+ decreased and was lower than the control group(P<0.01);serum CEA

CYFRA-21-1 levels in the two groups were decreased than that before treatment

after treatment

the observation group than in the control group (P<0.01). Conclusion: APS combined with I125 in the treatment of advanced NSCLC

can improve the quality of life of patients

improve immune function

and has certain anti tumor effect and synergistic effect on the I125

worthy of further study.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据